Previous 10 | Next 10 |
Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has closed on its warran...
2024-04-18 16:12:22 ET More on Longeveron Longeveron Inc. (LGVN) Q4 2023 Earnings Call Transcript Longeveron stock rallies 85% on Alzheimer's presentation (update) Longeveron stock rallies 75% amid public offering, business update Seeking Alpha’s Quant...
MIAMI, April 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart ...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 62.9% to $0.0373 on volume of 466,310,671 shares INVO BioScience Inc. (INVO) rose 139.5% to $1.82 on volume of 225,666,770 shares PROSHARES TRUST (SQQQ) rose 3.7% to $11.86 on volume of 167,545,988 ...
A recently published review has found that social vulnerability and frailty worsen as individuals age. When both are present, these conditions result in a considerably heightened decline in cognitive and physical function as well as mortality risk. So, what is frailty? Theoretically, frai...
2024-04-17 10:00:55 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Short interest in S&P 500 health stocks rises, Moderna among m...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) fell 0.7% to $0.177 on volume of 56,661,669 shares INVO BioScience Inc. (INVO) rose 233.6% to $2.535 on volume of 49,222,014 shares WiSA Technologies Inc. (WISA) rose 51.8% to $9.26 on volume of 27,894,316 sh...
2024-04-17 08:47:58 ET More on Longeveron Longeveron Inc. (LGVN) Q4 2023 Earnings Call Transcript Longeveron stock rallies 85% on Alzheimer's presentation (update) Longeveron stock rallies 75% amid public offering, business update Seeking Alpha’s Quant...
2024-04-17 08:21:19 ET Losers: Arrowroot Acquisition Corp ( AILE ) -34% . Hub Cyber Security Ltd ( HUBC ) -22% . Longeveron ( LGVN ) -18% announces exercise of warrants for $6.2 Million gross proceeds . Sage Therapeutics SAGE -19% after mi...
MIAMI, April 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart ...
News, Short Squeeze, Breakout and More Instantly...
Longeveron Inc. Company Name:
LGVN Stock Symbol:
NASDAQ Market:
Phase 2b clinical trial evaluating Lomecel-B TM in rare pediatric disease HLHS on track for completing enrollment by end of 2024 Data from Phase 2a clinical trial evaluating Lomecel-B TM in Alzheimer’s Disease selected for Featured Research Oral Presentation at 2024 Alzheimer...
Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, is reporting changes on its board of directors. The following transitions on the board have been announced: Richard Kender, retired SVP of bu...
Richard Kender, retired SVP of Business Development and Corporate Licensing for Merck & Co., Inc., has been appointed to the Longeveron Board...